This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the End-of-Phase 2

O c u p h i r e I n v e s t o r P r e s e n t a t i o n M a r c h 2 0 2

This presentation contains forward-looking statements within the meaning of the

Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the End-of-Phase 2 meeting with the FDA to align on late-stage registration endpoints and study parameters, the launching

of RYZUMVI, the continued development of PS and LDP, our partnership with Viatris, the strength of our cash position, and the potential of APX3330 as an oral treatment for patients with non-proliferative diabetic retinopathy. These

forward-looking statements relate to us, our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of

operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading "Risk Factors" included

in our Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. In some cases, you can identify forward-looking statements by the

following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms or other comparable

terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. These forward-looking

statements are based upon Ocuphire's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such

forward-looking statements as a result of various risks and uncertainties, including, without limitation: the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts;

regulatory requirements or developments; changes to or unanticipated events in connection with clinical trial designs and regulatory pathways; delays or difficulties in the enrollment of patients in clinical trials; substantial competition

and rapid technological change; our development of sales and marketing infrastructure; future revenue losses and profitability; our relatively short operating history; changes in capital resource requirements; risks related to the inability

of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; domestic and worldwide legislative, regulatory, political and economic developments; employee misconduct; changes

in market opportunities and acceptance; reliance on third-parties; future, potential product liability and securities litigation; system failures, unplanned events, or cyber incidents; the substantial number of shares subject to potential

issuance associated with our Equity Line of Credit arrangement with LPC; risks that our partnership with Viatris, or our other licensing arrangements, may not facilitate the commercialization or market acceptance of Ocuphire's product

candidates; future fluctuations in the market price of our common stock; the success and timing of commercialization of any of Ocuphire's product candidates; and obtaining and maintaining Ocuphire's intellectual property rights. The

foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive. Readers are urged to carefully review and consider the various disclosures made by us in this presentation

and in our reports filed with the SEC that advise interested parties of the risks and factors that may affect our business. All forward-looking statements contained in this presentation speak only as of the date on which they were made.

Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. 2 Disclosures and Forward-Looking Statements

Positioned to Transform the Treatment of Diabetic Retinopathy 3 NPDR market

calculated based on total DR market size of 8.9B in 2023 and NPDR revenue share of 70.38% in 2023. AMD, age-related macular degeneration; DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; FDA, Food & Drug

Administration; GA, geographic atrophy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; SPA, Special Protocol Assessment. Vabysmo is a trademark of Genentech, Inc.; Syfovre is a registered trademark

of Apellis Pharmaceuticals, Inc.; Meibo is a trademark of Bausch + Lomb Incorporated or its affiliates; Oxervate is a registered trademark of Domp Farmaceutici S.p.a.; RYZUMVI is a trademark of Ocuphire Pharma, Inc.; Xiidra is a registered

trademark of Bausch + Lomb Incorporated or its affiliates; Eysuvis and Inveltys are registered trademarks of Alcon, Inc. 1. Flaxel CJ, et al. Diabetic retinopathy preferred practice pattern . Ophthalmology. 2020;127:66-145. 2. Prevalence of

diabetic retinopathy. Centers for Disease Control and Prevention. Accessed December 21, 2023. https://www.cdc.gov/visionhealth/vehss/estimates/dr-prevalence.html 3. Data on file DR is the leading cause of blindness in working age adults,

impacting 10M patients in the US1,2 Most patients have early-stage disease (non-proliferative diabetic retinopathy), which is generally untreated and represents a $6B market3 Diabetic retinopathy market is large and underserved Current

therapies are invasive, often reserved for advanced DR, and do not address multiple disease pathways APX3330 may represent a promising oral option for slowing DR progression by inhibiting Ref-1, simultaneously addressing angiogenesis,

oxidative stress, and inflammation Oral APX3330 targets earlier-stage DR via multiple pathways Fewer APX3330-treated subjects experienced DR worsening compared to placebo, demonstrating efficacy on the FDA-confirmed endpoint of 3-step

DRSS worsening on binocular scale Fewer APX3330-treated subjects developed proliferative diabetic retinopathy (advanced DR) compared to placebo Phase 2 efficacy of APX3330 in slowing DR progression End-of-phase 2 meeting completed with FDA

alignment on primary endpoint SPA submitted to secure alignment on study design and statistical analysis plan Primed for upcoming pivotal Phase 2/3 study Over 60 years of combined Ophthalmology experience Senior management involved in the

research, development, and approval of numerous Ophthalmic products, including Vabysmo , Syfovre , Miebo , Oxervate , Ryzumvi , Xiidra , Eysuvis , and Inveltys In partnership with Viatris, Ryzumvi expected to launch 1H 2024 for reversal of

pharmacologically-induced mydriasis and two ongoing, funded Phase 3 studies in decreased visual acuity under low light conditions and presbyopia Provides for potential double-digit royalties and milestone payments Proven development

team Revenue-generating partnership

APX3330 is the Foundation of Our Retina Pipeline PRODUCT

CANDIDATE INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY APPROVAL MILESTONES APX3330 Oral pill Diabetic Retinopathy EOP2 meeting SPA submission APX2009 Geographic Atrophy Preclinical

proof-of-concept APX2014 Retina Select drug delivery technology and evaluate target disease Eye drop Licensed to Viatris Reversal of pharmacologically- induced mydriasis Approved (Sept 2023) Launch expected 1H

2024 Presbyopia VEGA-2 Ph 3 topline data (Q4 2023) Decreased visual acuity under low light (mesopic) conditions SPA Agreement LYNX-2 pivotal studies *RYZUMVI is indicated for the treatment of pharmacologically-induced mydriasis

produced by adrenergic agonists (eg, phenylephrine) or parasympatholytic agents (eg, tropicamide). EOP, end of Phase; SPA, Special Protocol Assessment. RYZUMVI is a trademark of Ocuphire Pharma, Inc. 4

Diabetic Retinopathy is the Leading Cause of Vision Loss in Working-Age Adults

in the US 5 C L I N I C A L P R E S E N T A T I O N Blood vessels weaken, bulge, close off, or leak into the retina Growth of new abnormal blood vessels in the retina (neovascularization), vitreous hemorrhage, and scar tissue C O M M O

N S Y M P T O M S Asymptomatic (early stages) Floaters, blurry vision, dark spots (later stages) Vision loss, blindness T R E A T M E N T "Watch and wait" is SoC IVI anti-VEGF injections (advanced disease) IVI anti-VEGF injections

Panretinal laser photocoagulation Vitrectomy surgery anti-VEGF, anti-vascular endothelial growth factor therapy; DR, diabetic retinopathy; IVI, intravitreal injection; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic

retinopathy; SoC, standard of care. 1. Diabetic Eye Disease. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-

disease#:~:text=Diabetic%20retinopathy%20is%20the%20most,of%20blindness%20by%2095%20percent. Accessed on March 20, 2024. 2. Diabetic retinopathy: Causes, symptoms, treatment. American Academy of Ophthalmology. Accessed on December 22, 2023.

https://www.aao.org/eye-health/diseases/what-is-diabetic-retinopathy 3. Flaxel CJ, et al. Ophthalmology. 2020:P66-P145. Common complication of diabetes, and results from damage to blood vessels in the retina, progressively leading to vision

loss and impaired quality of life W h a t i s D R ? N P D R N o n - p r o l i f e r a t i v e D i a b e t i c R e t i n o p a t h y P r o l i f e r a t i v e P D R D i a b e t i c R e t i n o p a t h y

DR Progression Can Have a Significant Impact On Functional Vision NOTE: The

severity of vision loss varies between individuals with DR DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy. 1. [No authors listed]. ETDRS report number 12. Ophthalmology.

1991;98:823-833. 2. Diabetic Eye Disease. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-

problems/diabetic-eye-disease#:~:text=Diabetic%20retinopathy%20is%20the%20most,of%20blindness%20by%2095%20percent. Accessed on March 5, 2024. N P D R P D R M i n i m a l v i s u a l d i s r u p t i o n S i g n i f i c a n t v i s i o

n l o s s ~50% of patients with severe NPDR will progress to PDR in 1 year1 Treating diabetic retinopathy early can reduce the risk of blindness by 95%2 6

NPDR Represents a Large Segment of the Growing DR Market 2M P D R 2 38 M DI

ABETI CS 1 1 in 10 Americans have diabetes; 98M (over 1 in 3) have pre-diabetes1 10 M DR 2 ~1 in 4 diabetics (aged 40+) have DR1,2; Projected to increase to 19M+ by 20503 8M N P D R 2 NPDR market calculated based on total DR market

size of 8.9B in 2023 and NPDR revenue share of 70.38% in 2023.4 CAGR, compound annual growth rate; DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy. Lucentis is a registered

trademark of Genentech, Inc; Eylea is a registered trademark of Regeneron Pharmaceuticals, Inc.; Vabysmo is a trademark of Genentech, Inc. 1. Diabetes. A report card. Centers for Disease Control and Prevention. Accessed December 21, 2023.

https://www.cdc.gov/diabetes/library/socialmedia/infographics/diabetes.html 2. Prevalence of diabetic retinopathy. Centers for Disease Control and Prevention. Accessed December 21, 2023.

https://www.cdc.gov/visionhealth/vehss/estimates/dr-prevalence.html 3. Lundeen EA, et al. JAMA Ophthalmol. 2023;141(8):747-754. 4. Grand View Research. Diabetic retinopathy market analysis, 2018-2023. 2023.

https://www.grandviewresearch.com/industry-analysis/diabetic-retinopathy-market APX3330 target market opportunity is $6B4 Expected to grow at CAGR of ~6% by 20304 APX3330 is the most advanced oral candidate in development for

NPDR 7 PDR market is addressed by 3 approved therapies

COMPANY DRUG PHASE TARGET ROA APX3330 Phase 2/3 Ref-1

inhibitor Oral Runcaciguat Phase 2 Guanylate cyclase activator Oral OPL-0401 Phase 2 ROCK 1/2 inhibitor Oral VX-1 Phase 2 AOC-3 inhibitor Oral RG7774 Discontinued CB2 receptor (cannabinoid) Oral OTT166 Phase 2 Missed

efficacy endpoint Integrin inhibitor Eye drop COMPANY DRUG PHASE TARGET ROA Eylea (aflibercept)* Commercial VEGF-A/B; PIGF Intravitreal Lucentis (ranibizumab) Commercial VEGF-A Intravitreal KSI-301 (tarcocimab) Phase

3 VEGF Intravitreal EYP-1901 Phase 2 Voloronib (TKI) Intravitreal BI 764524 Phase 2 Anti-Sema3A Intravitreal OTX-TKI Phase 1 Axitinib (TKI) Intravitreal RGX-314 Phase 2 AAV8 VEGF Suprachoroidal (gene therapy) APX3330 has

the Potential to be the First Oral Treatment for DR N o n - i n v a s i v e t h e r a p i e s AAV8, adeno-associated virus 8; AOC-3, Amine oxidase copper-containing 3; CB2, cannabinoid receptor 2; DR, diabetic retinopathy; PIGF, placental

growth factor; Ref-1, reduction-oxidation effector factor-1; ROCK, rho kinase; Sema3A, semaphorin3A; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor. Eylea is a registered trademark of Regeneron Pharmaceuticals,

Inc.; Lucentis is a registered trademark of Genentech, Inc. Note: Two Tyrosine Kinase and a Plasma Kallikrein Inhibitors failed as orals in Phase 2 due to dose limiting adverse events (e.g., liver and cardiovascular). *Trials to support

approval: Panorama clinical trial; Trials to support approval: Protocol I & T and Rise & Ride; Failed as oral/systemic treatments in retina due to dose limiting toxicity Sources: Company websites and www.clinicaltrials.gov I n v a

s i v e t h e r a p i e s ( I V T / s u p r a c h o r o i d a l ) 8

APX3330 The most advanced oral program currently in development for diabetic

Steroid injections / implants ONLY target inflammation Anti-VEGF injections

ONLY target angiogenesis Ref-1 Mediates Multiple Pathways Involved in DR Current Invasive Treatments Only Target a Single Pathway 10 NOTE: Ozurdex , Xipere , and Iluvien are not indicated for the treatment of DR. Lucentis is a

registered trademark of Genentech, Inc; Eylea is a registered trademark of Regeneron Pharmaceuticals, Inc.; Vabysmo is a trademark of Genentech, Inc.; Ozurdex is a registered trademark of Allergan, Inc., an AbbVie company; Xipere is a

registered trademark of Clearside Biomedical, Inc.; Iluvien is a registered trademark of Alimera Sciences, Inc. Nrf2, nuclear factor erythroid 2-related factor 2; Ref-1, reduction-oxidation effector factor-1; VEGF, vascular endothelial

growth factor. 1. Logsdon DP, et al. Sci Rep. 2018;8:13759. 2. Li Y, et al. Redox Biology 2. 2014;485-494. FDA R e f - 1 O x i d a t i v e S t r e s s I n c re a s e d ox i d a t i ve s t re s s v i a N r f 2 i n a c t i v a t i o n E

l e v a t e d V E G F e x p re s s i o n A n g i o g e n e s i s I n f l a m m a t i o n E l e v a t e d i n f l a m m a t o ry c y t o k i n e s

APX3330 Inhibits Ref-1-mediated Angiogenesis, Oxidative Stress, and

Inflammation Nrf2, nuclear factor erythroid 2-related factor 2; Ref-1, reduction-oxidation effector factor-1; TNF- : tumor necrosis factor alpha; VEGF, vascular endothelial growth factor. 1. Logsdon DP, et al. Sci Rep. 2018;8:13759. 2. Li

Y, et al. Redox Biology 2. 2014;485-494. FDA O x i d a t i v e S t r e s s A n g i o g e n e s i s I n f l a m m a t i o n A P X 3 3 3 0 I n h i b i t s R e f - 1 R e f - 1 I n c re a s e d ox i d a t i ve s t re s s v i a N r f 2 i

n a c t i v a t i o n E l e v a t e d V E G F e x p re s s i o n E l e v a t e d i n f l a m m a t o ry c y t o k i n e s 11

95 100 105 110 115 120 0 12.5 25 50 500 450 400 350 300 250 200 150 100 50 0 VEGF

concentrations (% of control) * p<0.05 APX3330 restores physiologic VEGF levels1 APX3330 (30 m) - - oxLDL (150 g/mL) - - TNF- (pg/ml) IL-6 (pg/ml) * * * *p<0.05 *p<0.05 * % increase in APE1 repair

activity * Restoration of physiologic VEGF treats pathologic disease while allowing a favorable tolerability profile Reduced oxidative stress should improve integrity of the neurovascular unit * * * In vitro Data Validates Three

Clinically Meaningful Pathways in DR APX3330 reduces pro-inflammatory cytokines (in macrophages)2 APX3330 increases DNA oxidative repair and neuronal

protection3 14000 12000 10000 8000 6000 4000 2000 0 12000 10000 8000 6000 4000 2000 0 APX3330 ( g/mL) 0 0 6.25 12.5 25 LPS (1 g/mL) - 90 APX3330 ( m) APX3330 ( g/mL) 0 0 6.25 12.5 25 LPS (1

g/mL) - * APE-1, apyrimidinic endonuclease 1; ARPE, spontaneously arising retinal epithelial cell line; LPS, lipopolysaccharide; oxLDL, oxidized low density lipoprotein, TNF- , tumor necrosis factor-alpha; IL-6, interleukin 6;

VEGF, vascular endothelial growth factor. 1. Li Y, et al. Redox Biology 2. 2014;485-494. 2. Jedinak A, et al. Anticancer Research. 2011;379-386. 3. Kelley MR, et al. PLoS One. 2014;9:e106485. 12 1 2 3

ZETA-1 Clinical Trial A Phase 2 Randomized, Placebo-Controlled, Double-Masked

Study of APX3330 in DR is Complete

Primary endpoint: % of subjects with a 2 step improvement in monocular ETDRS

DRSS at week 24 Study eye: DR graded moderately severe to severe NPDR or mild PDR (monocular DRSS 47, 53, or 61) Fellow eye: No exclusion* Baseline DRSS Scores Placebo (n=52) APX3330 (n=51) DRSS Score - Study Eye 47 Moderately

severe to severe NPDR 18 (35%) 22 (43%) 53 Moderately severe to severe NPDR 28 (54%) 25 (49%) 61 Mild PDR 6 (12%) 4 (8%) DRSS Score - Fellow Eye 43 or Lower Mild to moderate NPDR or better 12 (23%) 15 (29%) 47 Moderately

severe to severe NPDR 22 (42%) 15 (29%) 53 Moderately severe to severe NPDR 11 (21%) 14 (28%) 61 Mild PDR 4 (8%) 1 (2%) 65 or Higher Moderate to severe PDR 3 (6%) 4 (8%) Note: 15 fellow eyes were CST>320 microns

(center-involved DME) *Two APX3330 subjects did not have available DRSS scores in the fellow eye at screening. BID, twice-daily; CST, central subfield thickness; DME, diabetic macular edema, DRSS, Diabetic Retinopathy Severity Scale; NPDR,

non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy. Source: ZETA-1 Table 14.1.2.1 APX3330 600mg/day (BID) Placebo (BID) 1:1 randomization Week 0 Week 4 Week 12 Week 24 Primary Endpoint ZETA-1 Phase 2

Study Design and Demographics N = 103 14

ETDRS monocular severity scale1 Binocular person-level scale1 Moderately

severe Severe or very severe Mild Subjects graded based on fundus photographs (images of the retina taken with a fundus camera). DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic

Retinopathy Study; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy. 1. Chew EY, et al. N Engl J Med. 2010;363:233-44. Binocular DRSS is a Validated and Well-Established Scale to Evaluate Systemic

Therapies 15 Moderate N O D R N P D R P D R Severe Very mild Moderate Mild 10 20 35 43 47 53 60-61 65 71+ 1 2,3 4,5 6,7 8,9 10,11 12,13 14,15 16,17+ 3-step worsening on the binocular DRSS is considered clinically